These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 27886160)

  • 21. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
    Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
    Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer.
    Choe JC; Choi JH; Choi JH; Ahn J; Park JS; Lee HW; Oh JH; Lee HC; Cha KS; Hong TJ
    Clin Cardiol; 2018 Oct; 41(10):1308-1314. PubMed ID: 30239009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
    Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
    J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temporal Trends of Cardiac Chambers Function with Trastuzumab in Human Epidermal Growth Factor Receptor II-Positive Breast Cancer Patients.
    Moustafa S; Murphy K; Nelluri BK; Northfelt D; Shah P; Lee H; Wilansky S; Naqvi TZ; Meyer S; Mookadam F
    Echocardiography; 2016 Mar; 33(3):406-15. PubMed ID: 26498324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serial Measurements of Left Ventricular Systolic and Diastolic Function by Cardiac Magnetic Resonance Imaging in Patients with Early Stage Breast Cancer on Trastuzumab.
    Song L; Brezden-Masley C; Ramanan V; Ghugre N; Barfett JJ; Chan KKW; Haq R; Petrella T; Dhir V; Jimenez-Juan L; Chacko BR; Kotha V; Connelly KA; Yan AT
    Am J Cardiol; 2019 Apr; 123(7):1173-1179. PubMed ID: 30683420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
    Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
    Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.
    Martinello R; Becco P; Vici P; Airoldi M; Del Mastro L; Garrone O; Barone C; Pizzuti L; D'Alonzo A; Bellini E; Milani A; Bonzano A; Montemurro F
    Breast J; 2019 May; 25(3):444-449. PubMed ID: 30932296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method.
    Nakano S; Takahashi M; Kimura F; Senoo T; Saeki T; Ueda S; Tanno J; Senbonmatsu T; Kasai T; Nishimura S
    Cardiol J; 2016; 23(3):270-80. PubMed ID: 27173679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy.
    El-Sherbeny WS; Sabry NM; Sharbay RM
    J Echocardiogr; 2019 Jun; 17(2):76-83. PubMed ID: 30099714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reliability of Left Ventricular Ejection Fraction from Three-Dimensional Echocardiography for Cardiotoxicity Onset Detection in Patients with Breast Cancer.
    Lorenzini C; Lamberti C; Aquilina M; Rocca A; Cortesi P; Corsi C
    J Am Soc Echocardiogr; 2017 Nov; 30(11):1103-1110. PubMed ID: 28822666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
    Bouwer NI; Steenbruggen TG; Rier HN; Kitzen JJEM; Smorenburg CH; van Bekkum ML; de Jong PC; Drooger JC; Holterhues C; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
    Int J Cancer; 2022 Aug; 151(4):616-622. PubMed ID: 35403708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
    BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
    Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
    Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.
    Keramida K; Farmakis D; Bingcang J; Sulemane S; Sutherland S; Bingcang RA; Ramachandran K; Tzavara C; Charalampopoulos G; Filippiadis D; Kouris N; Nihoyannopoulos P
    Eur J Heart Fail; 2019 Apr; 21(4):529-535. PubMed ID: 30811091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
    Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
    Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of early sub-clinical trastuzumab-induced cardiotoxicity in breast cancer patients.
    Dores H; Abecasis J; Correia MJ; Gândara F; Fonseca C; Azevedo J; Arroja I; Martins A; Mendes M
    Arq Bras Cardiol; 2013 Apr; 100(4):328-32. PubMed ID: 23525273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy.
    Upshaw JN; Finkelman B; Hubbard RA; Smith AM; Narayan HK; Arndt L; Domchek S; DeMichele A; Fox K; Shah P; Clark A; Bradbury A; Matro J; Adusumalli S; Carver JR; Ky B
    JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 2):198-210. PubMed ID: 31542526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.